Thrombocytopenic Purpura after Measles-Mumps-Rubella Vaccination: A Systematic Review of the Literature and Guidance for Management

Journal of Pediatrics

Volumn 156, Issue 4, 2010, Pages 623-628

  Mantadakis, Elpis ^a   Farmaki, Evangelia ^b   Buchanan, George R ^c  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b Aristotle University of Thessaloniki   (Greece)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MEASLES MUMPS RUBELLA VACCINE;

ARTICLE; BIBLIOGRAPHIC DATABASE; BLEEDING; BLOOD SMEAR; BLOOD TRANSFUSION; BRAIN HEMORRHAGE; DISEASE COURSE; DISEASE DURATION; GASTROINTESTINAL HEMORRHAGE; HEMATURIA; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNIZATION; INCIDENCE; LUNG HEMORRHAGE; MEASLES; MEDLINE; MUMPS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT DISEASE; RUBELLA; SYSTEMATIC REVIEW; THROMBOCYTE COUNT; VACCINATION;

HUMANS; INCIDENCE; MEASLES-MUMPS-RUBELLA VACCINE; PRACTICE GUIDELINES AS TOPIC; PURPURA, THROMBOCYTOPENIC; RISK FACTORS; VACCINATION;

EID: 77949654482     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpeds.2009.10.015     Document Type: Article

References (47)

1. Jefferson T., Price D., Demicheli V., and Bianco E. European Research Program for Improved Vaccine Safety Surveillance (EUSAFEVAC) Project. Unintended events following immunization with MMR: a systematic review. Vaccine 21 (2003) 3954-3960
2. Institute of Medicine. Measles and mumps vaccines. In: Stratton K.R., Howe C.J., and Johnston Jr. R.B. (Eds). Adverse events associated with childhood vaccines. Evidence bearing on causality (1994), National Academy Press, Washington, DC 163-169
3. Bachand A.J., Rubenstein J., and Morrison A.N. Thrombocytopenic purpura following live measles vaccine. Am J Dis Child 113 (1967) 283-285
4. Wilhelm D.J., and Paegle R.D. Thrombocytopenic purpura and pneumonia following measles vaccination. Am J Dis Child 113 (1967) 534-537
5. Saxton N.L. Thrombocytopenic purpura following the administration of attenuated live measles vaccine. J Iowa Med Soc 57 (1967) 1017-1018
6. Alter H.J., Scanlon R.T., and Schechter G.P. Thrombocytopenic purpura following vaccination with attenuated measles virus. Am J Dis Child 115 (1968) 111-113
7. Kiefaber R.W. Thrombocytopenic purpura after measles vaccination (letter). N Engl J Med 305 (1981) 225
8. Neiderud J. Thrombocytopenic purpura after a combined vaccine against morbilli, parotitis and rubella. Acta Paediatr Scand 72 (1983) 613-614
9. Azeemuddin S. Thrombocytopenic purpura after combined vaccine against measles, mumps, and rubella (letter). Clin Pediatr (Phila) 26 (1987) 318
10. De Ritis L., and Pecorari R. Thrombopenic purpura following measles vaccination. Pediatr Med Chir 12 (1990) 161-163
11. Rejjal A.L., Britten G., and Nazer H. Thrombocytopenic purpura following measles-mumps-rubella vaccination. Ann Trop Paediatr 13 (1993) 103-104
12. Drachtman R.A., Murphy S., and Ettinger L.J. Exacerbation of chronic thrombocytopenic purpura following measles-mumps-rubella immunization. Arch Pediatr Adolesc Med 148 (1994) 326-327
13. Vlacha V., Forman E.N., Miron D., and Peter G. Recurrent thrombocytopenic purpura after repeated measles-mumps-rubella vaccination. Pediatrics 97 (1996) 738-739
14. Kashyape S.S., and Kashyape P.S. Thrombocytopenia following MMR vaccination Indian Pediatr 42 (2005) 80-82
15. Update. Measles-United States, January-July 2008. MMWR Morb Mortal Wkly Rep 57 (2008) 893-896
16. Wise R.P., Bonhoeffer J., Beeler J., Donato H., Downie P., Matthews D., et al., Brighton Collaboration Thrombocytopenia Working Group. Thrombocytopenia: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 25 (2007) 5717-5724
17. Pedersen-Bjergaard U., Andersen M., and Hansen P.B. Thrombocytopenia induced by noncytotoxic drugs in Denmark 1968-91. J Intern Med 239 (1996) 509-515
18. Nieminen U., Peltola H., Syrjälä M.T., Mäkipernaa A., and Kekomäki R. Acute thrombocytopenic purpura following measles, mumps and rubella vaccination. A report on 23 patients. Acta Paediatr 82 (1993) 267-270
19. Farrington P., Pugh S., Colville A., Flower A., Nash J., Morgan-Capner P., et al. A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines. Lancet 345 (1995) 567-569
20. Jonville-Béra A.P., Autret E., Galy-Eyraud C., and Hessel L. Thrombocytopenic purpura after measles, mumps and rubella vaccination: a retrospective survey by the French regional pharmacovigilance centres and pasteur-mérieux sérums et vaccins. Pediatr Infect Dis J 15 (1996) 44-48
21. Miller E., Waight P., Farrington C.P., Andrews N., Stowe J., and Taylor B. Idiopathic thrombocytopenic purpura and MMR vaccine. Arch Dis Child 84 (2001) 227-229
22. Black C., Kaye J.A., and Jick H. MMR vaccine and idiopathic thrombocytopaenic purpura. Br J Clin Pharmacol 55 (2003) 107-111
23. Rajantie J., Zeller B., Treutiger I., and Rosthöj S. NOPHO ITP working group and five national study groups. Vaccination associated thrombocytopenic purpura in children. Vaccine 25 (2007) 1838-1840
24. France E.K., Glanz J., Xu S., Hambidge S., Yamasaki K., Black S.B., et al., Vaccine Safety Datalink Team. Risk of immune thrombocytopenic purpura after measles-mumpsrubella immunization in children. Pediatrics 121 (2008) e687-e692
25. Nakayama T., and Onoda K. Vaccine adverse events reported in post-marketing study of the Kitasato Institute from 1994 to 2004. Vaccine 25 (2007) 570-576
26. Koch J., Leet C., McCarthy R., Carter A., and Cuff W. Adverse events temporally associated with immunizing agents: 1987 report. Can Dis Weekly Rep 15 (1989) 151-158
27. Bottiger M., Christenson B., Romanus V., Taranger J., and Strandell A. Swedish experience of two dose vaccination programme aiming at eliminating measles, mumps, and rubella. Br Med J (Clin Res Ed) 295 (1987) 1264-1267
28. Fescharek R., Quast U., Maass G., Merkle W., and Schwarz S. Measles-mumps vaccination in the FRG: an empirical analysis after 14 years of use. II. Tolerability and analysis of spontaneously reported side effects. Vaccine 8 (1990) 446-456
29. Bayer W.L., Sherman F.E., Michaels R.H., Szeto I.L., and Lewis J.H. Purpura in congenital and acquired rubella. N Engl J Med 273 (1965) 1362-1366
30. Lokietz H., and Reynold F.A. Postrubella thrombocytopenic purpura. J Lancet 85 (1965) 226-230
31. Annual Report of the Health Department of the City of Baltimore: 1964, May 1, 1965.
32. Ueda K., Sasaki F., Tokugawa K., Segawa K., and Fujii H. The 1976-1977 rubella epidemic in Fukuoka city in southern Japan: epidemiology and incidences of complications among 80,000 persons who were school children at 28 primary schools and their family members. Biken J 27 (1984) 161-168
33. Jadavji T., Scheifele D., and Halperin S. Canadian Paediatric Society/Health Canada Immunization Monitoring Program. Thrombocytopenia after immunization of Canadian children, 1992 to 2001. Pediatr Infect Dis J 22 (2003) 119-122
34. Beeler J., Varricchio F., and Wise R. Thrombocytopenia after immunization with measles vaccines: review of the vaccine adverse events reporting system (1990 to 1994). Pediatr Infect Dis J 15 (1996) 88-90
35. Stowe J., Kafatos G., Andrews N., and Miller E. Idiopathic thrombocytopenic purpura and the second dose of MMR. Arch Dis Child 93 (2008) 182-183
36. Bibby A.C., Farrell A., Cummins M., and Erlewyn-Lajeunesse M. Is MMR immunization safe in chronic idiopathic thrombocytopenic purpura?. Arch Dis Child 93 (2008) 354-355
37. Kühne T., Buchanan G.R., Zimmerman S., Michaels L.A., Kohan R., Berchtold W., et al., Intercontinental Childhood ITP Study Group. A prospective comparative study of 2540 infants and children with newly diagnosed idiopathic thrombocytopenic purpura (ITP) from the Intercontinental Childhood ITP Study Group. J Pediatr 143 (2003) 605-608
38. Rosthøj S., Hedlund-Treutiger I., Rajantie J., Zeller B., Jonsson O.G., Elinder G., et al., NOPHO ITP Working Group. Duration and morbidity of newly diagnosed idiopathic thrombocytopenic purpura in children: a prospective Nordic study of an unselected cohort. J Pediatr 143 (2003) 302-307
39. Zeller B., Rajantie J., Hedlund-Treutiger I., Tedgard U., Wesenberg F., Jonsson O.G., Nopho I.T.P., et al. Childhood idiopathic thrombocytopenic purpura in the Nordic countries: epidemiology and predictors of chronic disease. Acta Paediatr 94 (2005) 178-184
40. Ackroyd J.F. Three cases of thrombocytopenic purpura occurring after rubella. Quart J Med 42 (1949) 299-319
41. Sladden R.A. Thrombocytopenic purpura and rubella. Br Med J 2 5372 (1963) 1587-1588
42. Morse E.E., Zinkham W.H., and Jackson D.P. Thrombocytopenic purpura following rubella infection in children and adults. Arch Intern Med 117 (1966) 573-579
43. Braun M.M. Toward better vaccine safety data and safer vaccination. Pediatrics 121 (2008) 625-626
44. Lilleyman J.S. Management of childhood idiopathic thrombocytopenic purpura. Br J Haematol 105 (1999) 871-875
45. Zeller B., Helgestad J., Hellebostad M., Kolmannskog S., Nystad T., Stensvold K., et al. Immune thrombocytopenic purpura in childhood in Norway: a prospective, population-based registration. Pediatr Hematol Oncol 17 (2000) 551-558
46. Cohn J. Thrombocytopenia in childhood: an evaluation of 433 cases. Scand JHaematol 16 (1976) 226-240
47. th ed (2009), American Academy of Pediatrics, Elk Grove Village, IL 444-455